一个新的双载荷ADC平台,集成exatecan和triptolide,以提高抗瘤效率和克服抗性

Pengfei Ren1, Menglong Guan1, Jiao Tang1

  • 1Chengdu Kanghong Pharmaceutical Group Co., Ltd, Chengdu, China.

PubMed
概括

这项研究引入了一种新型的双有效载荷抗体-药物合物 (ADC),可以克服癌症药物耐药性. 通过结合两个抑制剂,这种ADC显示出显著的抗瘤活性和有利的安全性.

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K